Lonza Pharma & Biotech and Innosieve Diagnostics announced today an exclusive distribution agreement for rapid bioburden testing technology. This agreement expands Lonza’s extensive offering of ...
The Global Bioburden Testing Market has experienced consistent growth, with a compound annual growth rate (CAGR) of 12-15%. This growth is driven by tightening regulatory standards and an increasing ...
(MENAFN- GlobeNewsWire - Nasdaq) The bioburden testing market is set to grow significantly due to increased demand in pharmaceuticals and medical devices and strict regulatory standards. Key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results